Rosuvastatin for lowering lipids

We found 108 trials involving 19,596 participants

Stephen P Adams

2014

Scholarcy highlights

  • Rosuvastatin is one of the most potent statins and is currently widely prescribed
  • A pooled estimate for all doses compared to placebo showed an risk ratio of 0.84 suggesting no effect of rosuvastatin on withdrawals due to adverse effects in these short-term trials
  • These large reductions reflect a reduction in synthesis of cholesterol by the liver and indicate that liver HMG CoA reductase is being inhibited by approximately one half over this dose range
  • For the doses where there is a large number of trials and participants, it can be seen that estimates of the effect of rosuvastatin on the lipid parameters are similar with the two different trial designs
  • All doses of rosuvastatin did not change WDAEs as compared to placebo
  • Participants participants were not receiving any lipid-altering agents within 3 months of trial no washout required 12-week before-and-after trial men and women with impaired fasting glucose, hypertension and mixed dyslipidaemia low-density lipoprotein-C >160 mg/dl TG >150 mg/dl 20 participants were randomized to manidipine and rosuvastatin 10 mg/day 20 participants were randomized to olmesartan and rosuvastatin 10 mg/day exclusion criteria: diabetes mellitus, cardiovascular disease, renal disease hypothyroidism, liver dysfunction and females not taking sufficient contraceptive measures Rosuvastatin 10 mg/day baseline TC : 6.745 mmol/l Rosuvastatin 10 mg/day baseline LDL-C : 4.345 mmol/l Rosuvastatin 10 mg/day baseline highdensity lipoprotein-C : 1.435 mmol/l Rosuvastatin 10 mg/day baseline non-HDL-C: 5.315 mmol/l manidipine and rosuvastatin 10 mg/day for 12 weeks olmesartan and rosuvastatin 10 mg/day for 12 weeks both sets of data were combined per cent change from baseline at 12 weeks of serum TC, LDL-C, HDL-C and non HDL-C
  • Based on an informal comparison rosuvastatin was determined to be about three-fold more potent than atorvastatin in reducing total cholesterol and low-density lipoprotein-cholesterol

Need more features? Save interactive summary cards to your Scholarcy Library.